NervGen Pharma (NASDAQ:NGEN) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of NervGen Pharma (NASDAQ:NGEN) have received a consensus rating of “Moderate Buy” from the six ratings firms that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, two have assigned a buy rating and two have issued a strong buy rating on the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $14.00.

A number of equities analysts have recently issued reports on NGEN shares. Wall Street Zen cut NervGen Pharma from a “hold” rating to a “strong sell” rating in a report on Saturday, August 15th. Weiss Ratings cut NervGen Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, August 4th. HC Wainwright upgraded NervGen Pharma to a “strong-buy” rating in a research report on Tuesday, April 28th. TD Cowen assumed coverage on NervGen Pharma in a research note on Thursday, June 11th. They issued a “buy” rating for the company. Finally, Zacks Research upgraded shares of NervGen Pharma to a “hold” rating in a research report on Wednesday, April 29th.

Institutional Investors Weigh In On NervGen Pharma

Institutional investors have recently made changes to their positions in the business. Empery Asset Management LP bought a new position in shares of NervGen Pharma during the 2nd quarter valued at $8,240,000,000. Stonepine Capital Management LLC bought a new stake in NervGen Pharma in the second quarter worth $559,657,000. Finally, AXQ Capital LP bought a new stake in NervGen Pharma in the second quarter worth $89,000.

NervGen Pharma Price Performance

Shares of NASDAQ:NGEN opened at $2.00 on Tuesday. NervGen Pharma has a 52-week low of $1.58 and a 52-week high of $6.30. The stock has a fifty day moving average of $1.84. The stock has a market capitalization of $161.26 million and a price-to-earnings ratio of -4.35.

NervGen Pharma (NASDAQ:NGEN) last released its quarterly earnings results on Thursday, August 13th. The company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.28). Equities analysts predict that NervGen Pharma will post -0.4 earnings per share for the current fiscal year.

NervGen Pharma Company Profile

NervGen Pharma Corp. is a clinical-stage biotechnology company focused on developing therapies to promote nerve repair and restore neurological function following injury or disease. The company advances regenerative approaches intended to address damage in the central and peripheral nervous systems, pursuing programs that aim to translate preclinical repair concepts into human treatments.

The company’s lead investigational candidate is NVG-291, which is being evaluated in clinical studies for indications that include spinal cord injury, neuropathic conditions and neurodegenerative disease settings.